EUVIMEDEUVIMED entdecken
Crossref

Therapeutic‐like activity of cannabidiolic acid methyl ester in the MK‐801 mouse model of schizophrenia: Role for cannabinoid CB1 and serotonin‐1A receptors

Brandon Richardson iD, Courtney Clarke, Jacqueline Blundell, Francis R Bambico

European Journal of Neuroscience · 2024

DOI: 10.1111/ejn.16278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neuroscience, 2024. Verfasst von Brandon Richardson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial University of Newfoundland and Labrador, St. John's, Newfoundland, Canada. Hauptthemen laut MEDLINE: Schizophrenia, Dizocilpine Maleate, Receptor, Serotonin, 5-HT1A, Receptor, Cannabinoid, CB1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Project Scheme Grant, Canadian Institutes of Health Research, Canada Graduate Scholarship-Masters (CGS M) Award (B.R.), Natural Sciences and Engineering Research Council of Canada, Discovery Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schizophrenia is a psychotic disorder with an increasing prevalence and incidence over the last two decades. The condition presents with a diverse array of positive, negative, and cognitive impairments. Conventional treatments often yield unsatisfactory outcomes, especially with negative symptoms. We investigated the role of prefrontocortical (PFC) N‐methyl‐D‐aspartate receptors (NMDARs) in the pathophysiology and development of schizophrenia. We explored the potential therapeutic effects of cannabidiolic acid (CBDA) methyl ester (HU‐580), an analogue of CBDA known to act as an agonist of the serotonin‐1A receptor (5‐HT1AR) and an antagonist of cannabinoid type 1 receptor (CB1R). C57BL/6 mice were intraperitoneally administered the NMDAR antagonist, dizocilpine (MK‐801, .3 mg/kg) once daily for 17 days. After 7 days, they were concurrently given HU‐580 (.01 or .05 μg/kg) for 10 days. Behavioural deficits were assessed at two time points. We conducted enzyme‐linked immunosorbent assays to measure the concentration of PFC 5‐HT1AR and CB1R. We found that MK‐801 effectively induced schizophrenia‐related behaviours including hyperactivity, social withdrawal, increased forced swim immobility, and cognitive deficits. We discovered that low‐dose HU‐580 (.01 μg/kg), but not the high dose (.05 μg/kg), attenuated hyperactivity, forced swim immobility and cognitive deficits, particularly in female mice. Our results revealed that MK‐801 downregulated both CB1R and 5‐HT1AR, an effect that was blocked by both low‐ and high‐dose HU‐580. This study sheds light on the potential antipsychotic properties of HU‐580, particularly in the context of NMDAR‐induced dysfunction. Our findings could contribute significantly to our understanding of schizophrenia pathophysiology and offer a promising avenue for exploring the therapeutic potential of HU‐580 and related compounds in alleviating symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaDizocilpine MaleateReceptor, Serotonin, 5-HT1AReceptor, Cannabinoid, CB1Mice, Inbred C57BLDisease Models, AnimalAnimalsMaleMiceFemaleCannabinoidsReceptors, N-Methyl-D-AspartateAntipsychotic Agents

Stichwörter der Autor:innen

MK‐801cannabidiolic acid methyl ester (HU‐580)cannabinoid CB1 receptormouse modelschizophreniaserotonin‐1A receptor

Substanzen

Dizocilpine MaleateReceptor, Serotonin, 5-HT1AReceptor, Cannabinoid, CB1CannabinoidsHtr1a protein, mouseReceptors, N-Methyl-D-AspartateAntipsychotic Agents

Autor:innen und Institutionen

  • Memorial University of Newfoundland and Labrador, St. John's, Newfoundland, Canada.

ORCID-Profile: Brandon Richardson

Förderung

  • Canadian Institutes of Health Research, Project Scheme Grant
  • Canadian Institutes of Health Research, Canada Graduate Scholarship-Masters (CGS M) Award (B.R.)
  • Natural Sciences and Engineering Research Council of Canada, Discovery Grant
  • Institute of Neurosciences, Mental Health and Addiction
  • Canadian Institutes of Health Research
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Richardson, B., Clarke, C., Blundell, J., & Bambico, F. R. (2024). Therapeutic‐like activity of cannabidiolic acid methyl ester in the MK‐801 mouse model of schizophrenia: Role for cannabinoid CB1 and serotonin‐1A receptors. European Journal of Neuroscience. https://doi.org/10.1111/ejn.16278

Vancouver

Richardson B, Clarke C, Blundell J, Bambico FR. Therapeutic‐like activity of cannabidiolic acid methyl ester in the MK‐801 mouse model of schizophrenia: Role for cannabinoid CB1 and serotonin‐1A receptors. European Journal of Neuroscience. 2024. doi:10.1111/ejn.16278

BibTeX
@article{Richardson2024,
  author = {Richardson, Brandon and Clarke, Courtney and Blundell, Jacqueline and Bambico, Francis R},
  title = {Therapeutic‐like activity of cannabidiolic acid methyl ester in the MK‐801 mouse model of schizophrenia: Role for cannabinoid CB1 and serotonin‐1A receptors},
  journal = {European Journal of Neuroscience},
  year = {2024},
  doi = {10.1111/ejn.16278}
}
Kostenlos starten →